Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2001-05-03
2004-02-03
Priebe, Scott D. (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C435S455000, C435S456000, C424S093200
Reexamination Certificate
active
06686196
ABSTRACT:
Throughout this application, various publications are referenced. The disclosures of these publications in their entireties, are hereby incorporated by reference into this application, in order to more fully describe the state of the art, as known to those skilled therein, as of the date of invention, described and claimed herein.
FIELD OF THE INVENTION
This invention relates to modified recombinant adenovirus (Ad) vectors which lack a gene or genes for replication of the adenovirus in a non-actively cycling cell but remain capable of specifically replicating in an actively cycling cells. These modified recombinant vectors are useful for regulating transgene expression in cells such as tumor cells and therefore, for treatment of a variety of cancers.
BACKGROUND OF THE INVENTION
Adenovirus Replication
Numerous studies in cell-free systems and in infected cells have established that Ad DNA replication takes place in two steps.
In the first step, DNA synthesis is initiated by the precursor to the terminal protein (pTP). pTP binds as a heterodimer with the Ad polymerase (Pol) to specific sites within the inverted terminal repeat (ITR) sequences. Ad DNA replication begins at both ends of the linear genome resulting in a daughter strand that is synthesized in the 5′ to 3′ direction displacing the parental strand with the same polarity.
Three non-exclusive mechanisms are proposed for the second stage, the replication of the displaced parental strand: i) displaced single strands can form partial duplexes by base pairing of the ITRs on which a second round of DNA synthesis may be initiated, ii) when two oppositely moving displacement forks meet, the two parental strands will no longer be held together and will separate, resulting in partially duplex and partially single-stranded (ss) molecules; synthesis is then completed on the displaced parental strands, and iii) displaced strands with opposite polarity resulting from initiation at two different molecular ends, can renature to form a double-stranded daughter molecule. Replication of DNA requires two components: DBP and polymerase. DBP is thought to stabilize the formation of the panhandle structure and the interstrand renaturation process. Polymerase synthesizes Ad DNA at a rate of 20-30 base pairs (bp) per second.
Ad DNA replication is a crucial prerequisite in Ad recombination. Suppressing Ad DNA replication diminishes Ad recombination.
Adenovirus Recombination
Ad DNA replication generates large amounts of stabilized ssDNA that has been shown to efficiently induce homologous recombination in bacteria. Electron microscopy (EM) studies demonstrated that the displaced parental single strand can be transferred to another duplex genome forming Holliday structures very similar to the structure described for homologous recombination in bacteria.
Early studies focused on Ad recombination revealed that Ad genomes can recombine until late in the infection cycle and each viral genome can undergo multiple recombination events. Population genetics of Ad genomes suggested a model similar to that proposed for T-even phages. More sophisticated studies analyzing cross-exchange of specific restriction sites demonstrated that recombination between Ad genomes can be detected only after the onset of viral DNA replication and that the degree of replication is proportional to the recombination frequency. Suppressing viral DNA replication unambiguously diminishes recombination.
Recombinant Ad vectors are widely used for gene transfer in vitro and in vivo (Hitt, M. M. et al., 1997.
Advances in Pharmacology.
40:137-205). First-generation AdE1− vectors used for gene transfer deleted the E1A/E1B genes and are, therefore, considered replication deficient in normal cells (Jones, N., and T. Shenk. 1979.
Proc Natl Acad Sci U S A.
76:3665-9).
The proteins encoded within the early region 1A (E1A-12S and E1A-13S) and 1B (E1B-55k and -19k) mediate viral replication by transactivating viral gene expression and deregulating the cell cycle [for review: (Shenk, T. 1996.
Adenoviridea,
p. 2111-2148. In B. N. Fields, Knipe, D. M., Howley, P. M. (ed.),
Fields Virology,
vol. 2. Lippincott-Raven Publisher, Philadelphia)]. E1A-12S and 13S are the first proteins expressed from the incoming viral genome and function as the main transactivators for other Ad transcription units, particularly the E2 and E4 regions that encode proteins for Ad DNA replication. E1A deregulates the cell cycle and induces cellular DNA synthesis by directly transactivating cellular genes [(e.g. c-myc (Hiebert, S. W. et al., 1989.
Proc Natl Acad Sci U S A.
86:3594-8), cdc2 (Kao, C. Y. et al., 1999.
J Biol Chem.
274:23043-51), hsp70 (Lum, L. S. et al., 1992.
Mol Cell Biol.
12:2599-605)], as well as by interacting with cell cycle regulatory proteins like pRb, pRb-related proteins (p107/p130), or p300 (Tiainen, M. et al., 1996.
Cell Growth Differ.
7:1039-50). Binding of E1A to pRb-family members releases transcription factors of the E2F family resulting in transcriptional upregulation of host genes; these genes are regulators or effectors of DNA synthesis [e.g. c-myc, Elf-1, myoD, DNA polymerase a, cyclins A and E, PCNA (Dyson, N., 1998.
Genes Dev.
12:2245-62)] which eventually drive quiescent cells into S-phase.
These and other cellular factors, whose activities peak during S-phase [e.g. the synthesis of deoxyribonucleotides (Bjorklund, S. et al., 1990.
Biochemistry.
29:5452-8; Engstrom, Y. et al., 1985.
J Biol Chem.
260:9114-6)], create an environment appropriate for viral DNA synthesis. However, in normal cells, E1A induced cell cycle deregulation results in the accumulation of p53, which stimulates p53 mediated G1 arrest (el-Deiry, W. S. et al., 993.
Cell.
75:817-25; Xiong, Y. et al., 1993.
Nature.
366:701-4) or apoptotic pathways (Miyashita, T., and J. C. Reed. 1995.
Cell.
80:293-9). Notably, E1A induced apoptosis can also occur through p53 independent pathways (Teodoro, J. G. et al., 1995.
Oncogene.
11:467-74).
Among the E1B proteins, the 19 kDa and 55 kDa proteins have been shown to cooperate with the E1A-13S product to initiate viral replication by down regulating p53 driven expression of cyclin D1; this is required for cells to progress through the G1 phase of the cell cycle (Spitkovsky, D. et al., 1995.
Oncogene.
10:2421-5). Another important function of the E1B proteins is to oppose p53-mediated apoptosis induced by E1A-12S. The E1B 55k protein in concert with E4-orf6 and E4-orf3 directly blocks p53, whereas E1B-19k appears to inhibit a p53-dependent, apoptotic downstream event similar to bcl-2 (Debbas, M. and E. White. 1993.
Genes Dev.
7:546-54; Rao, L. et al., 1992.
Proc Natl Acad Sci U S A.
89:7742-6). At late time points during lytic infection, E1B complexes to the E4orf6 protein, thereby enhancing the export of viral mRNA from the nucleus while, at the same time, inhibiting the transport of cellular mRNA (Babiss, L. E. and H. S. Ginsberg. 1984.
J Virol.
50:202-12; Ornelles, D. A., and T. Shenk. 1991.
J Virol.
65:424-9). E1B-55k inactivation of p53 has been hypothesized to be required for productive (wild type) adenovirus replication resulting in lytic infection (Bischoff, J. R. et al., 1996.
Science.
274:373-6). Consequently, it has been suggested that an E1B-55k mutant virus should replicate preferentially in p53 deficient tumor cells (Heise, C. et al., 1997.
Nat Med.
3:639-45; Heise, C. C. et al., 1999.
Cancer Res.
59:2623-8; Kirn, D. H., and F. McCormick. 1996.
Mol Med Today.
2:519-27; Wildner, O. et al., 1999.
Cancer Res.
59:410-3). However, a number of reports have discredited this idea by demonstrating that the ability of the E1B-55k mutant to productively replicate does not correlate with cellular p53 status (Goodrum, F. D., and D. A. Ornelles. 1998.
J Virol.
72:9479-90; Hall, A. R. et al., 1998.
Nat Med.
4:1068-72; Harada, J. N., and A. J. Berk. 1999.
J Virol.
73:5333-44; Hay, J. G. et al., 1999.
Hum Gene Ther.
10:579-90; Rothmann, T. et al., 1998.
J Virol.
72:9470-8;
Carlson Cheryl A.
Lieber Andre
Mi Jie
Steinwaerder Dirk S.
Mandel & Adriano
Priebe Scott D.
University of Washington
LandOfFree
Recombinant, modified adenoviral vectors for tumor specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant, modified adenoviral vectors for tumor specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant, modified adenoviral vectors for tumor specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3314423